PL371727A1 - Pochodne epotilonu stosowane w leczeniu pierwotnego raka wątroby i innych chorób nowotworowych - Google Patents

Pochodne epotilonu stosowane w leczeniu pierwotnego raka wątroby i innych chorób nowotworowych

Info

Publication number: PL371727A1
Authority: PL; Poland
Prior art keywords: treatment; progressing; cancer; radiotherapy; hepatoma
Prior art date: 2002-05-01

Application number

PL03371727A

Other languages

English (en)

Other versions

PL211114B1 (pl

Inventor

John David Rothermel

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-01

Filing date

2003-04-30

Publication date

2005-06-27

2003-04-30 Application filed by Novartis Ag filed Critical Novartis Ag

2005-06-27 Publication of PL371727A1 publication Critical patent/PL371727A1/pl

2012-04-30 Publication of PL211114B1 publication Critical patent/PL211114B1/pl

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
150000003883 epothilone derivatives Chemical class 0.000 title abstract 2
206010073071 hepatocellular carcinoma Diseases 0.000 title abstract 2
230000002250 progressing effect Effects 0.000 abstract 6
238000001959 radiotherapy Methods 0.000 abstract 5
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
206010009944 Colon cancer Diseases 0.000 abstract 1
208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
201000001342 Fallopian tube cancer Diseases 0.000 abstract 1
208000013452 Fallopian tube neoplasm Diseases 0.000 abstract 1
206010027476 Metastases Diseases 0.000 abstract 1
206010033128 Ovarian cancer Diseases 0.000 abstract 1
206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
208000026149 Primary peritoneal carcinoma Diseases 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
229940125697 hormonal agent Drugs 0.000 abstract 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
229960004768 irinotecan Drugs 0.000 abstract 1
201000001441 melanoma Diseases 0.000 abstract 1
230000009401 metastasis Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000013059 nephrectomy Methods 0.000 abstract 1
238000011474 orchiectomy Methods 0.000 abstract 1
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 abstract 1
229960001756 oxaliplatin Drugs 0.000 abstract 1
150000003058 platinum compounds Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Thiazole And Isothizaole Compounds (AREA)
Silicon Polymers (AREA)

PL371727A 2002-05-01 2003-04-30 Zastosowanie pochodnej epotilonowej w leczeniu choroby nowotworowej PL211114B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37706302P	2002-05-01	2002-05-01

Publications (2)

Publication Number	Publication Date
PL371727A1 true PL371727A1 (pl)	2005-06-27
PL211114B1 PL211114B1 (pl)	2012-04-30

Family

ID=29401440

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL371727A PL211114B1 (pl)	2002-05-01	2003-04-30	Zastosowanie pochodnej epotilonowej w leczeniu choroby nowotworowej

Country Status (23)

Country	Link
US (2)	US20050282873A1 (pl)
EP (1)	EP1503756B1 (pl)
JP (1)	JP2005528414A (pl)
KR (1)	KR20040106422A (pl)
CN (1)	CN1649585A (pl)
AT (1)	ATE439130T1 (pl)
AU (1)	AU2003227702B2 (pl)
BR (1)	BR0309711A (pl)
CA (1)	CA2483826C (pl)
CY (1)	CY1109607T1 (pl)
DE (1)	DE60328772D1 (pl)
DK (1)	DK1503756T3 (pl)
ES (1)	ES2330324T3 (pl)
IL (1)	IL164783A (pl)
MX (1)	MXPA04010853A (pl)
NO (1)	NO20045249L (pl)
NZ (1)	NZ536178A (pl)
PL (1)	PL211114B1 (pl)
PT (1)	PT1503756E (pl)
RU (1)	RU2358730C2 (pl)
SI (1)	SI1503756T1 (pl)
WO (1)	WO2003092683A1 (pl)
ZA (1)	ZA200408492B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1649585A (zh) *	2002-05-01	2005-08-03	诺瓦提斯公司	用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物
US20060235059A1 (en) *	2003-09-02	2006-10-19	Dilea Clifford	Cancer treatment with epothilones
US8394365B2 (en)	2003-09-17	2013-03-12	Nektar Therapeutics	Multi-arm polymer prodrugs
EP1640004A1 (en) *	2004-09-24	2006-03-29	Schering Aktiengesellschaft	Use of epothilones in the treatment of bone metastases and bone tumors or cancers
EP1824458A1 (en) *	2004-11-18	2007-08-29	Bristol-Myers Squibb Company	Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
US20060121511A1 (en)	2004-11-30	2006-06-08	Hyerim Lee	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JP2008536479A (ja)	2005-02-11	2008-09-11	ユニバーシティオブサザンカリフォルニア	ジスルフィド架橋を有するタンパク質の発現法
US8008256B2 (en)	2006-05-01	2011-08-30	University Of Southern California	Combination therapy for treatment of cancer
MX2008004267A (es) *	2008-03-28	2009-09-28	Posi Visionary Solutions Llp	Metoclopramida de liberacion prolongada de 12 horas.
MX2008004268A (es) *	2008-03-28	2009-09-28	Posi Visionary Solutions Llp	Metoclopramida de liberacion prolongada de 24 horas.
US8802394B2 (en)	2008-11-13	2014-08-12	Radu O. Minea	Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN101747326B (zh) *	2010-01-12	2012-07-25	山东大学	18元大环内酯类埃博霉素化合物及其应用
CN103037903A (zh)	2010-05-18	2013-04-10	天蓝制药公司	用于治疗自身免疫性疾病或其它疾病的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6204388B1 (en) *	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) *	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6194181B1 (en) *	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) *	1998-02-25	2001-10-16	Novartis Ag	Cancer treatment with epothilones
WO2000050423A1 (en) *	1999-02-22	2000-08-31	Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf)	C-21 modified epothilones
GB9918429D0 (en) *	1999-08-04	1999-10-06	Novartis Ag	Organic compounds
CN1649585A (zh) *	2002-05-01	2005-08-03	诺瓦提斯公司	用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物

2003
- 2003-04-30 CN CNA038097702A patent/CN1649585A/zh active Pending
- 2003-04-30 PT PT03725129T patent/PT1503756E/pt unknown
- 2003-04-30 BR BR0309711-0A patent/BR0309711A/pt active Search and Examination
- 2003-04-30 PL PL371727A patent/PL211114B1/pl not_active IP Right Cessation
- 2003-04-30 DE DE60328772T patent/DE60328772D1/de not_active Expired - Lifetime
- 2003-04-30 MX MXPA04010853A patent/MXPA04010853A/es active IP Right Grant
- 2003-04-30 SI SI200331688T patent/SI1503756T1/sl unknown
- 2003-04-30 NZ NZ536178A patent/NZ536178A/en not_active IP Right Cessation
- 2003-04-30 WO PCT/EP2003/004581 patent/WO2003092683A1/en not_active Ceased
- 2003-04-30 ES ES03725129T patent/ES2330324T3/es not_active Expired - Lifetime
- 2003-04-30 US US10/512,504 patent/US20050282873A1/en not_active Abandoned
- 2003-04-30 EP EP03725129A patent/EP1503756B1/en not_active Expired - Lifetime
- 2003-04-30 KR KR10-2004-7017468A patent/KR20040106422A/ko not_active Ceased
- 2003-04-30 RU RU2004135307/15A patent/RU2358730C2/ru not_active IP Right Cessation
- 2003-04-30 JP JP2004500867A patent/JP2005528414A/ja active Pending
- 2003-04-30 AU AU2003227702A patent/AU2003227702B2/en not_active Ceased
- 2003-04-30 CA CA2483826A patent/CA2483826C/en not_active Expired - Fee Related
- 2003-04-30 DK DK03725129T patent/DK1503756T3/da active
- 2003-04-30 AT AT03725129T patent/ATE439130T1/de active
2004
- 2004-10-20 ZA ZA200408492A patent/ZA200408492B/en unknown
- 2004-10-21 IL IL164783A patent/IL164783A/en not_active IP Right Cessation
- 2004-11-30 NO NO20045249A patent/NO20045249L/no not_active Application Discontinuation
2008
- 2008-03-11 US US12/046,017 patent/US20080161369A1/en not_active Abandoned
2009
- 2009-11-11 CY CY20091101180T patent/CY1109607T1/el unknown

Also Published As

Publication number	Publication date
JP2005528414A (ja)	2005-09-22
AU2003227702B2 (en)	2007-07-26
ES2330324T3 (es)	2009-12-09
AU2003227702A1 (en)	2003-11-17
CA2483826C (en)	2012-04-17
PL211114B1 (pl)	2012-04-30
NZ536178A (en)	2007-10-26
HK1073601A1 (en)	2005-10-14
RU2004135307A (ru)	2005-09-10
PT1503756E (pt)	2009-10-28
IL164783A (en)	2011-08-31
RU2358730C2 (ru)	2009-06-20
EP1503756A1 (en)	2005-02-09
MXPA04010853A (es)	2005-02-14
CA2483826A1 (en)	2003-11-13
DK1503756T3 (da)	2009-11-16
BR0309711A (pt)	2005-02-09
EP1503756B1 (en)	2009-08-12
US20080161369A1 (en)	2008-07-03
ZA200408492B (en)	2006-09-27
NO20045249L (no)	2005-01-26
US20050282873A1 (en)	2005-12-22
CN1649585A (zh)	2005-08-03
IL164783A0 (en)	2005-12-18
CY1109607T1 (el)	2014-08-13
DE60328772D1 (de)	2009-09-24
SI1503756T1 (sl)	2010-01-29
WO2003092683A1 (en)	2003-11-13
ATE439130T1 (de)	2009-08-15
KR20040106422A (ko)	2004-12-17

Legal Events

Date	Code	Title	Description
2015-07-31	LAPS	Decisions on the lapse of the protection rights	Effective date: 20140430

Publication	Publication Date	Title
CY1109607T1 (el)	2014-08-13	Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων
PH12019502586A1 (en)	2020-09-28	N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
NO2017019I1 (no)	2017-05-04	Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
NZ580009A (en)	2012-06-29	Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
RU2012140185A (ru)	2014-03-27	Ингибирование ангиогенеза
SG170809A1 (en)	2011-05-30	Diarylthiohydantoin compounds
RU2014108042A (ru)	2015-09-10	Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
NO20044475L (no)	2004-11-10	2-(2,6-diklorfenyl)-diarulimidazoler
EA201201154A1 (ru)	2013-12-30	Ингибиторы фосфатидилинозит-3-киназы и способы их применения
NZ603303A (en)	2014-05-30	Peptide epoxyketones for proteasome inhibition
RU2018102963A (ru)	2019-08-16	Производные анилинпиримидина и их применения
MY150756A (en)	2014-02-28	Tumor theraphy with an anti-vegf antibody
RU2013131241A (ru)	2015-01-20	Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
ATE424208T1 (de)	2009-03-15	Proteinkinaseinhibitoren
DE602005015304D1 (de)	2009-08-20	Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer
ATE461713T1 (de)	2010-04-15	Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
RU2006142418A (ru)	2008-07-20	Способ лечения рака
JP2023517671A5 (pl)	2024-03-05
TW200724158A (en)	2007-07-01	Combination therapy in the treatment of cancer
ATE406375T1 (de)	2008-09-15	Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
DK1572715T3 (da)	2007-04-02	Steroidforbindelser med antitumor-aktivitet
TN2009000427A1 (en)	2011-03-31	Use of hdac inhibitors for the treatment of gastrointestinal cancers
WO2005048956A3 (en)	2005-08-04	Estradiol-related compounds and methods of use as anti-tumor agents
EA200600987A1 (ru)	2006-10-27	Применение сирамезина в лечении злокачественных опухолей